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Abstract
Background: The number of copies of the HLA-DRB1 shared epitope, and the minor alleles of the STAT4 rs7574865 and the
PTPN22 rs2476601 polymorphisms have all been linked with an increased risk of developing rheumatoid arthritis. In the
present study, we investigated the effects of these genetic variants on disease activity and disability in patients with early
arthritis.
Methodology and Results: We studied 640 patients with early arthritis (76% women; median age, 52 years), recording
disease-related variables every 6 months during a 2-year follow-up. HLA-DRB1 alleles were determined by PCR-SSO, while
rs7574865 and rs2476601 were genotyped with the Taqman 59 allelic discrimination assay. Multivariate analysis was
performed using generalized estimating equations for repeated measures. After adjusting for confounding variables such as
gender, age and ACPA, the TT genotype of rs7574865 in STAT4 was associated with increased disease activity (DAS28) as
compared with the GG genotype (b coefficient [95% confidence interval] = 0.42 [0.01–0.83], p = 0.044). Conversely, the
presence of the T allele of rs2476601 in PTPN22 was associated with diminished disease activity during follow-up in a dose-
dependent manner (CT genotype =20.27 [20.56– 20.01], p = 0.042; TT genotype =20.68 [21.64– 20.27], p = 0.162). After
adjustment for gender, age and disease activity, homozygosity for the T allele of rs7574865 in STAT4 was associated with
greater disability as compared with the GG genotype.
Conclusions: Our data suggest that patients with early arthritis who are homozygous for the T allele of rs7574865 in STAT4
may develop a more severe form of the disease with increased disease activity and disability.
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Introduction
Rheumatoid arthritis (RA) is caused by an interaction between
genetic and environmental factors that leads to a break in
immunological self-tolerance. Twin concordance data suggest that
RA has a heritability rate of 50–60% [1]. The HLA region is the
main genetic factor accounting for this heritability, particularly the
HLA-DRB1 alleles that encode the shared epitope (SE) [2]. In
addition, during the past few years, genome-wide association
studies and candidate gene association studies have led to the
identification of new genes associated with the risk of developing
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RA [3]. The role of PTPN22 and STAT4 as genetic markers of
susceptibility to RA has been extensively replicated in different
populations [3–5].
In contrast to the clear association between the risk of
developing RA and alleles in HLA-DRB1, PTPN22, and STAT4,
it remains unclear whether these genetic factors affect disease
severity once immunological self-tolerance is broken. Some
authors have reported an association between the SE and
radiological progression, systemic complications and cardiovascu-
lar events in RA [6–9]. However, several studies of the role of
genetic factors outside the HLA region in the radiological
progression of RA have produced contradictory results [10], and
little information is available on the impact of genetic factors on
disease activity and disability [11].
When our study was designed, only the presence of the SE and
the polymorphisms in PTPN22 and STAT4 were clearly associated
with an increased risk of developing RA in distinct Spanish
populations. Thus, the objective of our study was to determine
whether the presence of these genetic markers contributes to a
poorer disease course and increased disability in patients with early
arthritis (EA).
Methods
Ethics Statement
The local ethics committees reviewed and approved the
protocols of both EA Clinical Registers, and all the patients
signed an informed consent form prior to inclusion in the study.
Objective
The hypothesis of the present study is that the genetic variants
that confer a high risk of developing RA are also associated with a
worse clinical course of disease. The specific objective was to
determine whether the presence of the SE, the minor alleles of
STAT4 rs7574865 or PTPN22 rs2476601 polymorphisms affect
disease activity and disability in EA patients.
Participants
The study sample comprised 641 patients with EA who
attended the Hospital Universitario (HU) La Paz (355 patients)
and HU La Princesa (286 patients). Inclusion criteria included 2
or more swollen joints for at least 4 weeks and symptoms for
less than a year. Only data from patients fulfilling the 1987
American College of Rheumatology criteria for RA [12] within
the 2-year follow-up (n= 464) or with chronic undifferentiated
arthritis (UA: n= 177) were analyzed. The protocol included 5
visits during the two-year follow-up period and at each visit, the
following data were collected and entered into an electronic
database: clinical and demographic information; disease dura-
tion at the beginning of follow-up; Disease Activity Score of 28
tender and swollen joint counts (DAS28) [13]; global disease
activity on a 100-mm visual analogue scale assessed by both the
patient and the physician; the score from the Health Assessment
Questionnaire (HAQ; Spanish version) [14]; and the results of
laboratory tests including the erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), rheumatoid factor (RF,
assessed by nephelometry; positive .20 IU/ml), and anti-
citrullinated peptide antibody (ACPA, measured by enzyme
immunoassay: Euro-Diagnostica Immunoscan RA; positive
.50 IU/ml).
Description of the Procedures
Genotyping. DNA was obtained from peripheral blood using
standard methods, and the samples were genotyped for the
PTPN22 rs2476601 and the STAT4 rs7574865 genetic variants
using a predesigned SNP Genotyping Assay (Applied Biosystems,
Part numbers: C_16021387_20 and C_29882391_10, respective-
ly: Foster City, California, USA). Polymerase chain reactions
(PCRs) were carried out according to the manufacturer’s
instructions and after PCR, the genotype of each sample was
automatically attributed by measuring allele-specific fluorescence
on an ABI Prism 7900 Sequence Detection System using SDS
version 2.3 (Applied Biosystems). Duplicate samples and negative
controls were included to verify the genotyping accuracy.
Table 1. Baseline characteristics of patients with early arthritis.
Rheumatoid arthritis (n =464)
Undifferentiated arthritis
(n = 177) Total (n =641) p value
Age (years) 53 (42–68) 51 (38–65) 52 (41–66) 0.022
Female gender (%) 75.6 76.8 75.9 NS
Disease duration(weeks) 18 (10–26) 14 (7–28) 17 (8–27) 0.039
Smokers (%) 43.9 40.2 42.9 NS
DAS28-ESR 5.4 (4.4–6.4) 3.8 (2.9–4.7) 5 (3.8–6.1) ,0.001
HAQ 1.250 (0.750–1.875) 0.875 (0.375–1.375) 1.125 (0.625–1.750) ,0.001
CRP (mg/dl) 1.2 (0.5–3.1) 0.5 (0.3–1.2) 0.9 (0.3–2.7) ,0.001
ESR (mm/h) 32 (20–56) 20 (12–33) 28 (17–50) ,0.001
ACPA-positive (%) 61.2 18.4 49.4 ,0.001
RF positive (%) 67.7 16.9 53.7 ,0.001
Shared epitope (%) 59.2 35.9 52.6 ,0.001
STAT4 (%) (GG – GT – TT) 58–34.7–7.3 59–35.9–5.1 58.2–35–6.7 NS
PTPN22 (%) (CC – CT – TT) 83.3–15.7–0.9 86.4–13–0.6 84.1–15–0.9 NS
DAS28-ESR, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ACPA, anti-citrullinated
peptide antibodies; RF, rheumatoid factor; NS, non-significant.
doi:10.1371/journal.pone.0043661.t001
STAT4 rs7574865 as Biomarker in Early Arthritis
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Figure 1. Patients with early arthritis who were homozygous for the minor rs7574865 allele of STAT4 exhibited stronger disease
activity during the follow-up. The data are categorized according to the rs7574865 genotype of STAT4 (upper panel), the rs2476601 genotype of
PTPN22 (middle panel), and the number of copies of the shared epitope (SE; lower panel). Data represent the interquartile range (p75, upper edge of
the box; p25, lower edge; p50, midline), p95 (line above the box) and p5 (line below the box) of the DAS28 adjusted for gender and age (aDAS28).
Dots represent outliers.
doi:10.1371/journal.pone.0043661.g001
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HLA-DRB1 was genotyped using a reverse dot-blot kit with
sequence-specific oligonucleotide probes (Dynal RELITM SSO
HLA-DRB1 typing kit: Dynal Biotech, Bromborough, UK). When
necessary, high-resolution typing of HLA-DRB1_03 samples was
performed using Dynal AllSetTM SSP DRB1_03.
Statistical Analysis
Normally distributed quantitative variables were represented as
the mean (6 standard deviation: SD), while non-normally
distributed variables were represented as the median and
interquartile range (IQR). Qualitative variables were described
using an estimation of the proportions. Variables with a normal
distribution were analyzed by the t-test, while the Mann Whitney
or Kruskal-Wallis tests were used for variables with a non-normal
distribution. A x2 or Fishers exact test was used to compare
categorical variables.
Only patients whose DAS28 or HAQ scores were available on
at least two visits were considered for analysis. In addition, the
genotype of HLA-DRB1, PTPN22 or STAT4 was not available (lack
of DNA sample or undetermined) in 5%, 9% and 8.7% of cases,
respectively. Therefore, we used data from 1,718 visits (449
patients; 3.8 visits/patient) to analyze disease activity and data
from 1,813 visits (475 patients; 3.8 visits/patient) to analyze
disability. To identify factors that influenced disease activity
(DAS28 as the dependent variable) and disability (HAQ as the
dependent variable) during the follow-up, we fitted two popula-
tion-averaged models by generalized linear models nested by
patient and visit using the xtgee command of Stata 10.1 for
Windows (StataCorp LP, College Station, Texas, USA). The
population-averaged generalized estimating equations were first
modeled by adding all variables with a p value ,0.15 in
the bivariate analysis. The final models were constructed using
quasi-likelihood estimation based on the independence model
information criterion [15] and Wald tests, removing all variables
with p.0.15.
In addition, to confirm the results obtained for disease activity
we generated an ordered logistic model using the ologit command
of Stata. The dependent variable was the disease activity level,
using the cut-off points for DAS28 proposed by Prevoo et al.
(,2.6, remission; 2.6 to 3.2, low disease activity; 3.2 to 5.1,
moderate disease activity; .5.1 high disease activity [13]). The
analysis was modeled as described above for xtgee, with remission
considered 0 and low, moderate and high disease activity
represented as 1, 2 and 3. The ordered logistic analysis estimates
cut-off points that aid the interpretation of the coefficients for each
independent variable according to the levels of the dependent
variable.
Table 2. Effect of the presence of the shared epitope and the minor rs7574865 allele in STAT4 or rs2476601 in PTPN22 on disease
activity (DAS28) and disability (HAQ) in patients with early arthritis.
DAS28 HAQ
b Coeff. (95% CI) p value b Coeff. (95% CI) p value
Age (years):
,45 Ref. Ref.
45–65 0.54 (0.31–0.78) ,0.001 0.06 (20.01–0.14) 0.108
.65 0.71 (0.46–0.97) ,0.001 0.11 (0.02–0.19) 0.011
Gender
Man Ref. Ref.
Woman 0.48 (0.31–0.78) ,0.001 0.09 (0.02–0.17) 0.016
Diagnosis
RA Ref. Ref.
UA 20.50 (20.81– 20.20) 0.001 20.10 (20.192 20.01) 0.023
Positive ACPA 0.21 (0.01–0.42) 0.049 NS NS
DAS28 NI NI 0.30 (0.28–0.31) ,0.001
Shared epitope NS NS NS NS
STAT4 (rs7574865)
GG Ref. Ref.
GT 20.01 (20.21–0.20) 0.953 0.07 (0.01–0.14) 0.055
TT 0.42 (0.01–0.83) 0.044 0.19 (0.05–0.32) 0.007
PTPN22 (rs2476601)
CC Ref. Ref.
CT 20.27 (20.56– 20.01) 0.042 NS NS
TT 20.68 (21.64–0.27) 0.162 NS NS
Hospital
Center 1 Ref. Ref.
Center 2 20.35 (20.56– 20.13) ,0.001 NS NS
DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire; Coeff., coefficient; Ref., reference; RA, rheumatoid arthritis; UA, undifferentiated arthritis;
ACPA, anti-citrullinated peptide antibodies; NI, not included; NS, non-significant.
doi:10.1371/journal.pone.0043661.t002
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Results
Population
At baseline, patients with definitive RA exhibited increased
disease activity and disability, and higher acute phase reactant
values than patients with UA (Table 1). Similarly, the
percentages of RA patients positive for ACPA, RF and the
SE were significantly higher than among UA patients (Table 1).
However, UA patients were younger and tended to exhibit
shorter disease duration than RA patients (Table 1). No
significant differences were observed between the two subgroups
in the distribution of the polymorphisms in STAT4 and PTPN22
studied (Table 1).
The STAT4 rs7574865 Polymorphism is Associated with
the Evolution of Disease Activity in Early Arthritis Patients
The DAS28 values were significantly higher in elderly and
female patients, those fulfilling the RA criteria, those with positive
ACPA, and in patients from one of the centers (Table 2). After
adjusting for these confounding variables, patients who were
homozygous for the minor allele rs7574865 in STAT4 displayed
significantly higher DAS28 values (b coefficient 0.42 [95%
confidence interval: 0.01–0.83], p = 0.044: Table 2 and Figure 1),
whereas the presence of a SE copy had no significant effect on
disease activity. By contrast, the presence of the minor allele of
rs2476601 in PTPN22 was associated dose-dependently with lower
DAS28 values when compared with CC homozygous patients,
although this effect was not significant for the TT genotype due to
Figure 2. Effect of the rs7574865 and rs2476601 polymorphisms in STAT4 and PTPN22 on the level of disease activity in patients
with early arthritis. A) STAT4 genotypes: GG, white bars; GT, gray bars; TT, black bars. B) PTPN22 genotypes: CC, white bars; CT, gray bars; TT, black
bars. Data represent the proportion of visits in which remission, or low, moderate or high disease activity was recorded in the patients of each
genotype. This figure illustrates the findings presented in Table 3, in which the statistical significance of the differences in disease activity associated
with the genotype of each polymorphism is shown.
doi:10.1371/journal.pone.0043661.g002
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the low number of cases in our population (b coefficient for CT
genotype 20.27 [20.56– 20.01], p= 0.042; TT genotype 20.68
[21.64– 20.27], p = 0.162: Figure 1 and Table 2).
To confirm our findings and obtain additional information, we
analyzed the effects of these variables when disease activity is
categorized as remission, or as low, moderate or high disease
activity. Patients with the TT genotype of the rs7574865 allele in
STAT4 displayed greater disease activity than heterozygous or GG
genotype patients (Figure 2A). By contrast, the presence of a T
allele of rs2476601 in PTPN22 was associated with more visits at
weaker disease activity or remission (Figure 2B). Using this
approach, multivariate analysis revealed a stronger association
between the ACPA and TT genotype of rs7574865 in STAT4 and
increased levels of disease activity, without significant changes in
the contribution of the other independent variables when
compared with the previous model (gender, age, etc.: Table 3).
In addition, the cut-off points obtained in the ordered logistic
regression model (rows at the bottom of Table 3) suggest that
variables with positive coefficients, such as ACPA, gender or TT
genotype of rs7574865 in STAT4, increased disease activity to
moderate or high levels, while those with negative coefficients,
such as the minor allele of rs2476601 in PTPN22, decreased the
disease activity to the level of remission.
The Effect of the STAT4 rs7574865 Polymorphism on
Disability Reported by Early Arthritis Patients
As expected, disability was significantly correlated with DAS28
values. Moreover, female gender and older age were associated
with significantly higher HAQ values. After adjustment for these
confounding variables, we detected a significant dose-dependent
effect of the rs7574865 T allele of STAT4 on the HAQ value
(Table 2 and Figure 3). Neither the presence of the SE, or of the
PTPN22 rs2476601 minor allele, contributed to disability in our
population.
Discussion
To the best of our knowledge, this is the first study
demonstrating the influence of the STAT4 polymorphism
rs7574865 on disease course and disability in EA. STAT4 is a
member of the STAT family and it is implicated in the signals
mediated by interleukin (IL) 12, IL-23 and type 1 interferons [16].
Although the mechanism by which the minor allele of rs7574865
contributes to the rupture of self-tolerance is not well understood,
it is thought to involve dysregulation of helper T cell differentiation
towards TH1 and/or TH17 phenotypes [16]. Kariuki et al
reported that lupus patients with the minor rs7574865 allele of
STAT4 exhibit lower levels of serum interferon-a but a compar-
atively stronger biological responses to this cytokine [17].
Moreover, the minor allele of rs7574865 has also been associated
with severe disease in patients with systemic lupus erythematosus
[18]. Therefore, the more intense disease activity observed in
patients who were homozygous for the rs7574865 T allele may be
associated with increased sensitivity to IL-12, IL-23 or interferons.
By contrast, the presence of the minor allele of rs2476601 in
PTPN22 was associated with a trend towards diminished disease
activity. The functional effect of this polymorphism is open to
debate, although most studies suggest that the allele promotes a
gain of function and hence, an increased threshold for T cell
receptor (TCR) signaling that may lead to defective deletion of
autoreactive clones in the thymus [3,19]. Our results could support
this hypothesis, suggesting that once self-tolerance is broken in
patients with the rs2476601 T allele, autoreactive lymphocytes are
activated less efficiently through TCR.
Surprisingly, the presence of the SE was not associated with
increased disease activity or disability, probably due to the
inclusion of ACPA in the statistical models. However, excluding
this variable revealed no significant association between the
presence of the SE and a worse outcome (data not shown).
Although unexpected, there may be several explanations for this
finding: a) a proportion of SE carriers were non-smokers and thus,
they did not develop ACPA; b) some patients may be heterozygous
carriers of SE and carry protective DRB1 alleles; or c) SE may be
less important in RA patients from southern Europe than northern
Europe. Taken together, these findings suggest that ACPA is a
better marker of disease severity than SE. As with PTPN22,
specific genetic factors may confer a risk of developing the disease,
and while some may only modify disease severity, others may be
involved in both processes.
Few studies have evaluated the effects of genetic markers that
confer a risk of developing RA on disease activity and disability. In
one study, the influence of 5 susceptibility genes on disease severity
was analyzed, including that of DRB1, STAT4 and PTPN22 [11].
Table 3. Effect of the presence of the shared epitope and the
minor rs7574865 allele of STAT4 or rs2476601 in PTPN22 on
the level of disease activity.
b Coeff. (95% CI) p value
Age (years)
,45 Ref.
45–65 0.64 (0.42–0.86) ,0.001
.65 0.70 (0.47–0.94) ,0.001
Gender
Man Ref.
Woman 0.65 (0.44–0.86) ,0.001
Diagnosis
RA Ref.
UA 20.51 (20.79– 20.23) ,0.001
Positive ACPA 0.32 (0.13–0.51) 0.001
Shared epitope NS NS
STAT4 (rs7574865)
GG Ref.
GT 20.02 (20.21–0.16) 0.785
TT 0.56 (0.01–0.83) 0.002
PTPN22 (rs2476601)
CC Ref
CT 20.29 (20.54– 20.04) 0.025
TT 20.55 (21.44–0.33) 0.221
Hospital
Center 1 Ref.
Center 2 20.25 (20.45– 20.06) 0.01
Cutpoints
Remission/Low disease activity 20.10 (20.40–0.20) –
Low/Moderate disease activity 0.55 (0.24–0.85) –
Moderate/High disease activity 2.34 (2.02–2.66) –
DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire;
Coeff., coefficient; Ref., reference; RA, rheumatoid arthritis; UA, undifferentiated
arthritis; ACPA, anti-citrullinated peptide antibodies; NI, not included; NS, non-
significant.
doi:10.1371/journal.pone.0043661.t003
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Figure 3. Patients with early arthritis who are homozygous for the minor rs7574865 allele of STAT4 exhibit increased disability
during follow-up. The data are categorized according to the rs7574865 genotype of STAT4 (upper panel), the rs2476601 genotype of PTPN22
(middle panel), and the number of copies of the shared epitope (SE; lower panel). The data are presented as the interquartile range (p75, upper edge
of the box; p25, lower edge; p50, midline), the p95 (line above box) and p5 (line below the box) of the HAQ adjusted for gender and age (aHAQ). Dots
represent outliers.
doi:10.1371/journal.pone.0043661.g003
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Only a weak association was reported between TRAF1/C5 and
disease severity, as assessed by swollen joint counts, with no
association of STAT4 or the remaining genes. The conflicting
findings of this and our study may be due to the differences in
study design. As opposed to the cross-sectional cohort study
carried out previously, we performed a longitudinal study with
almost 4 observations per patient, providing a more detailed
picture of disease activity and disability. Our study involved
patients from 2 clinical centers, a confounding variable for which
the analysis of disease activity was adjusted. This is particularly
important given the poor reproducibility of tender and swollen
joint counts [20]. Furthermore, the study of Morgan and
coworkers only adjusted the analysis for disease duration, which
was longer than in our cohort. However, probably the most
significant factor contributing to the divergent findings is the
genetic background of the populations analyzed, as TRAF1/C5
and SE had a stronger influence on RA in the British population,
and STAT4 in the Spanish population.
In summary, our data suggest that homozygosity for the STAT4
rs7574865 minor allele is associated with a poorer disease course
and greater disability than homozygosity for the common allele of
this variant. We propose that the rs7574865 polymorphism may
be used as a molecular tool to identify patients that may benefit
from early aggressive treatment.
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